A low-grade increase of serum pancreatic exocrine enzyme levels by dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 100, Issue 3, 2013, Pages

  Tokuyama, Hirotake ^a,b   Kawamura, Harukiyo ^a,c   Fujimoto, Masaki ^a,c   Kobayashi, Kazuki ^a,c   Nieda, Mie ^d   Okazawa, Tetsuya ^b   Takemoto, Minoru ^a,c   Shimada, Fumio ^b  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION CHIBA MEDICAL CENTER   (Japan)

^c CHIBA UNIVERSITY HOSPITAL   (Japan)

^d Biotherapy Institute of Japan   (Japan)

Author keywords

DPP 4 inhibitor; Lipase; Pancreatic amylase; Pancreatitis; Type 2 diabetes mellitus

Indexed keywords

ALOGLIPTIN; ALPHA AMYLASE PANCREAS ISOENZYME; DIPEPTIDYL PEPTIDASE IV INHIBITOR; METFORMIN; SITAGLIPTIN; TRIACYLGLYCEROL LIPASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS; PANCREATITIS; SIDE EFFECT;

AGED; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; LIPASE; MALE; MIDDLE AGED; PANCREAS; PANCREATIC ALPHA-AMYLASES; PANCREATITIS; RETROSPECTIVE STUDIES;

EID: 84878493249     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2013.03.034     Document Type: Article

References (10)

1. Nauck M.A., Vilsboll T., Gallwitz B., Garber A., Madsbad S. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care 2009, 32(Suppl. 2):S223-S231.
2. Drucker D.J., Sherman S.I., Gorelick F.S., Bergenstal R.M., Sherwin R.S., Buse J.B. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010, 33:428-433.
3. Elashoff M., Matveyenko A.V., Gier B., Elashoff R., Butler P.C. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011, 141:150-156.
4. Butler P.C., Dry S., Elashoff R. GLP-1-based therapy for diabetes: what you do not know can hurt you. Diabetes Care 2010, 33:453-455.
5. Stulc T., Sedo A. Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects?. Diabetes Res Clin Pract 2010, 88:125-131.
6. Matveyenko A.V., Dry S., Cox H.I., Moshtaghian A., Gurlo T., Galasso R., et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 2009, 58:1604-1615.
7. Dore D.D., Seeger J.D., Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009, 25:1019-1027.
8. Engel S.S., Williams-Herman D.E., Golm G.T., Clay R.J., Machotka S.V., Kaufman K.D., et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010, 64:984-990.
9. Garg R., Chen W., Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010, 33:2349-2354.
10. Lando H.M., Alattar M., Dua A.P. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting. Endocr Pract 2012, 18:472-477.